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Abstract
Apical membrane antigen 1 (AMA-1) is considered to be a major candidate antigen for a malaria vaccine. Previous
immunoepidemiological studies of naturally acquired immunity to Plasmodium vivax AMA-1 (PvAMA-1) have shown a
higher prevalence of specific antibodies to domain II (DII) of AMA-1. In the present study, we confirmed that specific
antibody responses from naturally infected individuals were highly reactive to both full-length AMA-1 and DII. Also, we
demonstrated a strong association between AMA-1 and DII IgG and IgG subclass responses. We analyzed the primary
sequence of PvAMA-1 for B cell linear epitopes co-occurring with intrinsically unstructured/disordered regions (IURs). The B
cell epitope comprising the amino acid sequence 290–307 of PvAMA-1 (SASDQPTQYEEEMTDYQK), with the highest
prediction scores, was identified in domain II and further selected for chemical synthesis and immunological testing. The
antigenicity of the synthetic peptide was identified by serological analysis using sera from P. vivax-infected individuals who
were knowingly reactive to the PvAMA-1 ectodomain only, domain II only, or reactive to both antigens. Although the
synthetic peptide was recognized by all serum samples specific to domain II, serum with reactivity only to the full-length
protein presented 58.3% positivity. Moreover, IgG reactivity against PvAMA-1 and domain II after depletion of specific
synthetic peptide antibodies was reduced by 18% and 33% (P=0.0001 for both), respectively. These results suggest that the
linear epitope SASDQPTQYEEEMTDYQK is highly antigenic during natural human infections and is an important antigenic
region of the domain II of PvAMA-1, suggesting its possible future use in pre-clinical studies.
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Introduction
Malaria is one of the most debilitating parasitic diseases of
humans, with an estimated 225 million clinical cases and 781,000
deaths per year [1]. Of the species that infect humans, Plasmodium
vivax and Plasmodium falciparum are the two most important human
malaria parasites. Although deaths by P. vivax are rare compared
to the P. falciparum, P. vivax-induced malaria has an enormous
socioeconomic impact [2] and is now recognized as a cause of
severe and fatal malaria [3]. There are an increasing number of
publications reporting severe disease, including respiratory
distress, severe anemia and coma, as a result of P. vivax infection
[4,5]. Considering the emergence of chloroquine resistance [5,6]
and evidence of P. vivax strains with lower sensitivity to primaquine
[7], the development of a safe and affordable vaccine would be an
important addition to control strategies for infectious diseases like
malaria. Unfortunately, despite decades of research, effective
malaria vaccines are still not available [8].
Several asexual blood-stage antigens have been identified as
potential vaccine candidates and arestrongly supported by evidence
from studies using experimental models [9,10]; immune recognition
of these antigens has been demonstrated in exposed individuals in
malaria-endemic areas [11,12,13,14,15,16]. Among several vaccine
candidates, the Apical membrane antigen 1 (AMA-1) is a well-
characterized and functionally important merozoite protein and is
currently considered to be a major candidate antigen for a malaria
vaccine [17]. AMA-1 is a type I transmembrane protein that is
expressed in the late asexual schizont stage of the Plasmodium
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merozoites. Just prior to red blood cell (RBC) invasion, the mature
form of AMA-1 is transported to the merozoite surface membrane
asan83 kDaproteininP.falciparum,orasa 66 kDainothermalaria
species, where it is concentrated at the apical pole [18]; once on the
surface, this form is redistributed and undergoes two C-terminal
cleavages, giving rise to 48-kD and 44-kD soluble forms [19,
20,21,22]. AMA-1 is well-conserved in all Plasmodium species
examined and is also present in other apicomplexan parasites
[23,24,25,26]. Although its precise role is still unknown, the crucial
roleof AMA-1in the invasion process of Plasmodium species is clearly
established [26,27,28,29]. Several studies have demonstrated the
association of AMA-1 with erythrocyte binding [30,31] and
reorientation of merozoites on the surface of red blood cells [29].
The AMA-1 ectodomain contains three distinct domains (I, II,
and III) defined by eight intra-molecular disulfide bonds [32].
Several reports have previously shown that DII presents a high
degree of amino acid sequence conservation [33,34,35] and is
particularly the most immunogenic region of both P. falciparum
[36] and P. vivax AMA-1 (PvAMA-1) [37] ectodomains. The
determination of short and specific antigenic and/or immunogenic
regions within vaccine candidates would represent an advantage
over recombinant subunit vaccine development following the
large-scale production and generation of chimeric peptides
containing multiple relevant malarial epitopes.
In the present study, we describe the identification of a highly
antigenic linear B cell epitope within the PvAMA-1 vaccine
candidate and its further recognition in naturally P. vivax-infected
individuals. We confirmed that DII presented similar antigenicity
as the AMA-1 ectodomain, even when all IgG isotypes were
evaluated. Our results add further support for the development of
a PvAMA-1-based subunit vaccine against malaria vivax infection.
Materials and Methods
Study population and blood samples
A total of 214 blood samples from outclinic patients with
uncomplicated P. vivax malaria were collected at endemic areas of
Manaus (Amazonas state) and Cuiaba ´ (Mato Grosso state). All
patients were unrelated, as there were no family clusters, and they
were attended to and diagnosed at the Fundac ¸a ˜o de Medicina
Tropical Dr. Heitor Vieira Dourado, Manaus or Hospital Ju ´lio
Muller (Universidade Federal do Mato Grosso). Twenty healthy
adult blood donors were recruited for the study over the course of
several months from Belo Horizonte, Minas Gerais State, Brazil, a
non-endemic area for malaria. The study was approved by the
Ethical Committee on Research of Universidade Federal de Minas
Gerais (Protocol# ETIC 060/07). Blood was obtained after
receiving informed consent.
Venous blood was collected and was used to prepare thick
smears for microscopy to extract parasite DNA and to perform
serum separation. Parasitological evaluation was performed by
examination of 200 fields at l.0006 magnification under oil-
immersion microscopy. All slides were examined by three well-
trained microscopists from the Brazilian Ministry of Health. The
P. vivax mono-infection was confirmed by PCR as previously
described [38]. Infected individuals presented parasitemia levels of
3,72669,624 parasites/mL. The mean age of the naturally infected
and control groups were 38.6614.0 and 36.4611.9, respectively.
Recombinant Pv-AMA-1 and Domain II of Pv-AMA-1 (DII)
The recombinant proteins representing amino acids 43 to 487
of Pv-AMA-1 (ectodomain) [39,40] and the domain II (amino
acids 249 to 385) of Pv-AMA-1 were expressed in Escherichia coli,a s
previously described [37,39]. Briefly, the recombinant plasmid
pHIS-AMA-1 or pET-28a-AMA-1-DII were transformed into E.
coli BL-21 (DE3) expression host cells (Novagen, USA). Protein
expression was obtained by inoculating 8 ml of a culture grown
overnight in 200 ml of Luria broth (Invitrogen, USA) containing
100 mg/ml ampicillin (pHIS-AMA-1) or 30 mg/ml kanamycin
(pET-28a-AMA-1-DII) (Sigma, USA). The culture was grown with
continuous shaking at 37uC to an optical density of 0.6–0.8 at
600 nm and then induced for 3 hours under constant agitation at
37uC in the presence of 0.1 mM isopropyl-b-D-1-thiogalactopyr-
anoside (IPTG, Invitrogen). The recombinant proteins were
obtained from the pellet (ectodomain) or supernatant (domain II)
of the bacterial lysates.
The pellet containing the PvAMA-1 ectodomain was pro-
cessed for protein purification as described previously [37].
Briefly, the insoluble fraction, containing mostly inclusion bodies,
was washed four times with 10 mM sodium phosphate buffer,
pH 8.0, 1% 3-[(3-cholamidopropyl)-dimethyllammonio]-1-pro-
panesulfonate (CHAPSO, Sigma). The washed inclusion bodies
were then solubilized under continuous agitation in 10 mM
sodium phosphate buffer, pH 8.0, 0.5 M NaCl, and 10% (vol/
vol) glycerol containing 8 M urea at room temperature for 2 h.
After centrifugation at 23,000 g at 4uC for 30 min, the super-
natant was loaded onto a 1 ml column of pre-equilibrated Ni
2+-
NTA-agarose resin (Qiagen). The column was extensively washed
with solubilization buffer containing 5 mM imidazole (Sigma)
and then washed stepwise with decreasing concentrations of urea
(6 M – 1 M) in refolding buffer (20 mM sodium phosphate
buffer, pH 8.0, 0.5 M NaCl, 10% glycerol, 5 mM imidazole,
0.5 mM oxidized glutathione, 5 mM reduced glutathione, and
0.1% Triton X-100). Impurities were washed with five bed
volumes of refolding buffer containing 80 mM imidazole, and
PvAMA-1 was eluted with refolding buffer containing an
imidazole gradient (0.1–0.4 M). The fractions were analyzed by
SDS-PAGE and stained with coomassie blue. The fractions,
containing highly purified recombinant protein, were extensively
dialyzed against 50 mM sodium phosphate buffer, pH 8.0,
150 mM NaCl, 50% glycerol, and 0.1 mM DTT. The protein
concentration was determined by the Bradford method (Bio-Rad)
using bovine serum albumin (BSA, Sigma) as the standard.
The domain II of PvAMA-1 was purified as previously
described [37]. Briefly, the soluble protein-containing supernatant
was applied to a column with previously equilibrated Ni
2+-NTA-
agarose resin (sodium phosphate buffer 20 mM, pH 8.0, and
0.5 M NaCl). Bound proteins were eluted with a linear imidazole
gradient (0.1–0.4 M) in wash buffer (sodium phosphate buffer
20 mM, pH 8.0, 0.5 M NaCl, 1 mM PMSF and 20% glycerin,
pH 7.0). The fractions containing the recombinant proteins with a
high degree of purity were pooled and dialyzed against 20 mM
Tris-HCl, pH 8.0. After centrifugation at 18,000 g for 30 min at
4uC and filtration through a 0.22 mm membrane, the recombinant
protein was purified by ion-exchange chromatography using an
AKTA FPLC (GE Healthcare, Amersham, UK). The proteins
were eluted with a linear 0–1 M NaCl gradient in Tris-HCl buffer.
The 1 ml fractions were collected and analyzed by SDS PAGE.
The fractions containing the recombinant proteins with a high
degree of purity were pooled and extensively dialyzed against PBS.
The protein concentration was determined as described above.
Both the ectodomain and domain II of the Pv-AMA-1 antigen
were tested to determine the presence of Gram-negative bacterial
endotoxin using a chromogenic Limulus Amebocyte Lysate test
(QCL-1000, Cambrex, USA) according to the manufacturer’s
instruction and were found to be a non-significant source of
endotoxins (levels lower than detection limit of 5 EU/mL).
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To predict possible antigenic properties in AMA-1 using
bioinformatic tools, the entire PvAMA-1 sequence (Salvador
strain, Accession Number AAC16731) was downloaded from the
NCBI website (www.ncbi.nlm.nih.gov/protein). The signal pep-
tide and the C-terminal portion of PvAMA-1 (corresponding to
the transmembrane helix and intracellular portion) were manually
removed in order to obtain the ectodomain sequence.
Prediction of B cell epitopes
The prediction of B cell epitopes was carried out using the
program BepiPred [41]. This software takes a single sequence in
FASTA format as input, and each amino acid receives a
prediction score based on known Hidden Markov Models profiles
of known antigens and incorporates propensity scale methods
based on hydrophilicity and secondary structure prediction. The
lowest cut-off of 0.35 (as suggested by the BepiPred website) was
used in at least nine consecutive amino acids in order to consider
a given region as a valid linear B cell epitope. The epitope score
represents the average of the scores of individual amino acids
above the cut-off.
Prediction of intrinsically unstructured/disordered
proteins and domains
The prediction of intrinsically unstructured/disordered regions
(IURs) was carried out using the program IUPred [42]. This
software takes a single sequence in FASTA format as input and
predicts the potential IURs. IURs do not possess sufficient inter-
residue interactions to provide the stabilizing energy to overcome
the entropy loss during folding, therefore, adopting loop structures.
The final output is an individual score for each amino acid that
ranges from 0 (completely ordered) to 1 (completely unordered).
IURs were then predicted as a region spanning at least 9
contiguous amino acids with individual IUPred prediction score
for each amino acid above 0.35. Bio::Graphics and in-house perl
scripts were used to integrate the output of the BepiPred and
IUPred prediction results.
Synthesis, chromatography and mass spectrometry of
soluble peptide
The peptide sequence SASDQPTQYEEEMTDYQK, corre-
sponding to residues 290–307 of PvAMA-1 and having the best
prediction scores for B cell epitopes and IURs, was manually
synthesized by Fmoc chemistry [43]. The peptide was C-terminally
amidated. The peptide was deprotected and released from the resin
by TFA treatment in the presence of the appropriate scavengers.
The peptide was lyophilized, and its purity and mass were assessed
by HPLC and mass spectrometry, respectively.
The peptide was purified by high performance liquid chroma-
tography (HPLC) in a C18 reverse phase column (Vydac) (flow
rate 1.0 mL/min). The column was previously equilibrated with
0.1% aqueous trifluoroacetic acid (TFA), and the compound was
eluted by a linear gradient of 0.1% TFA in acetonitrile. Two peaks
were obtained (data not shown). The major peak was then
submitted to MALDI-TOF-TOF analyses. MS and tandem MS
analysis were performed using a MALDI-TOF-TOF AutoFlex
III
TM (Bruker Daltonics) instrument in positive/reflector mode
controlled by the FlexControl
TM software. Instrument calibration
was achieved using Peptide Calibration Standard II (Bruker
Daltonics) as a reference, and a-cyano-4-hydroxycinnamic acid
was used as matrix. The major peak was spotted to MTP
AnchorChip
TM 400/384 (Bruker Daltonics) targets using standard
protocols for the dried droplet method.
Antibody measurement
The enzyme-linked immunobsorbent assay (ELISA) for total
IgG antibodies was performed as previously described [39]. The
concentrations of antigens used were 1.0 mg/mL (PvAMA-1 and
DII) and 2.0 mg/mL (synthetic peptide). All samples were diluted
1:100 and evaluated for total IgG using peroxidase-conjugated
anti-human IgG antibodies (Sigma, St. Louis, MO). The ELISA
to detect the IgG subclasses was performed as previously
described [44]. The serum dilution used was 1:100, and the
mouse monoclonal antibodies to human IgG subclasses (clone
HP-6012 for IgG1, clone HP-6014 for IgG2, clone HP-6010 for
IgG3, and clone HP-6025 for IgG4, all from Sigma, USA) were
diluted according to the manufacturer’s specifications. Monoclo-
nal antibody binding was detected with peroxidase-conjugated
anti-mouse immunoglobulin (Sigma). The threshold of positivity
(cut-off value) was obtained by testing 20 different negative
control sera from individuals not exposed to malaria from Belo
Horizonte. The mean optical density value at 492 nm63S Df o r
duplicate determinations in negative sera was used as the cut-off
value for different subclasses. The thresholds of positivity were
0.32 for IgG, 0.15 for IgG1, 0.13 for IgG2, 0.1 for IgG3, and
0.06 for IgG4. The reactivity index (RI) was obtained to compare
the levels of different subclasses (IgG or IgG isotype) in the same
subject or among distinct groups. The RI value was calculated by
dividing the mean OD value for each test sample assayed by the
cut-off value for each subclass tested using sera from healthy
individuals (control group). Samples with an RI.1w e r e
considered positive.
Depletion ELISA
The depletion ELISAs were performed as previously described
[45]. Briefly, flat-bottom plates (BD Falcon, USA) were coated
overnight with 10 mg/mL of the peptide SASDQPTQYEEEMT-
DYQK, then washed, and blocked as described. Sera were added
to the plates at a 1:100 dilution and incubated overnight. On the
following day, sera were transferred to plates coated overnight
with PvAMA-1 and DII (1 mg/mL) after appropriate washing and
blocking, and the ELISAs were performed as described.
Statistical analysis
The one-sample Kolmogorov-Smirnoff test was used to deter-
mine whether a variable was normally distributed. All statistics were
carried out using Prism 5.0for Windows (GraphPad Software, Inc.).
The association between antibody response to PvAMA-1 ectodo-
main and DII was determined by Fisher’s exact test and Spearman
rank test. P values for the depletion assays were also determined by
Wilcoxon matched pairs test. A two-sided P value,0.05 was
considered significant.
Results
Antibodies from naturally P. vivax-infected individuals
present a similar pattern of recognition between the
PvAMA-1 ectodomain and PvAMA-1 domain II
In order to confirm previously published data showing that
the PvAMA-1 domain II is the immunodominant region of
this protein, the detection of specific antibodies against both the
PvAMA-1 ectodomain and DII was evaluated. Natural P.
vivax infection elicits considerable IgG production against both
PvAMA-1 ectodomain and DII antigens (Figure 1A). Although
the levels of specific IgG1, IgG2, IgG3 and IgG4 against
the AMA-1 ectodomain and domain DII varied in naturally
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antibodies to PvAMA-1 and DII was observed (Figure 1A).
The overall prevalence of donors who presented IgG antibodies
to each antigen was 62.4% (Figure 1B), although IgG-positive
responders to each antigen were not necessarily the same (data not
shown). Nevertheless, the frequency of IgG responders to the
ectodomain was significantly associated with the frequency of IgG
responders to DII (P,0.0418, Fisher’s exact test). Analysis of
specific IgG subclass production demonstrated that the association
between individuals who responded to DII and responders to the
full-length ectodomain was still significant (IgG1, P,0.0001;
IgG2, P=0.0002; IgG3, P,0.0001 and IgG4, P=0.0007; Fisher’s
exact test), confirming that DII is a highly antigenic region within
the PvAMA-1 protein. The strong association of specific IgG1
and IgG3 responses to the ectodomain and DII was further
demonstrated by a direct correlation between the reactivity index
for PvAMA-1 and the reactivity index for Domain II (P,0.0001,
r=0.7971 for IgG1 and ,0.0001, r=0.6499 for IgG3; Figure 2).
A similar significant correlation was detected for IgG2 and IgG4
antibodies, although a minor relationship between the response to
AMA-1 and DII was observed (data not shown).
Predictions of B-cell linear epitopes and intrinsically
unstructured/disordered regions in AMA-1 ectodomain
and chemical synthesis of a selected peptide
In order to explain the clear concordance between the IgG
response to the ectodomain and DII, we scanned the primary
sequence of AMA-1 ectodomain for possible B-cell linear epitopes
co-occurring with intrinsically unstructured/disordered regions
(IURs) (Figure 3). We observed several predicted epitopes
distributed within all three domains of the ectodomain, with no
apparent occurrence bias in any domain. Indeed, the three best
predicted epitopes (5
th,7
th and 10
th) are each distributed in a
distinct domain (domains I, II and III, respectively). The putative
IURs identified are also distributed in all three domains, with a
slight preference for occurrence in domain I. Of special interest,
however, was the overlap observed between the putative epitope
possessing the highest prediction score (7
th epitope, score of 1.234)
and the putative second best IUR (4
th IUR, score of 0.481)
predicted in domain II. The other two best predicted epitopes (5
th
and 10
th) occur in regions where no IUR were found (5
th)o ri n
regions where IUR have a low prediction score (10
th). Considering
the higher prediction scores for both evaluated features, the
Figure 1. Levels and proportion of specific IgG and IgG subclass antibodies to PvAMA-1 ectodomain and PvAMA-1 Domain II (DII).
(A) The Y-axis represents the mean reactivity index in naturally P. vivax-infected individuals. The dotted line shows the threshold of positivity
(reactivity index=1). (B) The Y-axis represents the mean prevalence of positivity observed in naturally P. vivax-infected individuals. Serum samples
(n=214) were tested at a 1:100 dilution.
doi:10.1371/journal.pone.0021289.g001
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synthesis and immunological testing.
Analytical chromatography of the predicted peptide SASDQPT-
QYEEEMTDYQK demonstrated a purity of 80–90% for the
synthetic compound (data not shown). Mass spectrometric analyses
also indicated an estimated mass of 2150.017 Da that corresponded
to the mass of the peptide (Figure S1).
Synthetic malarial peptide SASDQPTQYEEEMTDYQK is
highly recognized by specific antibodies to PvAMA-1 DII
The antigenicity of the synthetic peptide SASDQPTQYEE-
EMTDYQK was initially evaluated by the determination of the
specific IgG responses using sera from P. vivax-infected individuals
who were knowingly reactive to the PvAMA-1 ectodomain only,
domain II only, or reactive to both antigens. The data clearly show
that the peptide was recognized by all serum samples that
specifically recognized the domain II (Figure 4), thus confirming
the previous prediction of B cell epitopes. When serum from
infected individuals with no reactivity to DII (reactive only to
PvAMA-1) was assayed against the synthetic peptide, a 58.3%
positivity was observed (Figure 4), suggesting that the antibody
production to this region in natural infection is present but that it
is not sufficient to detect domain II. Of note, the highest reactivity
indices for the synthetic peptide were observed in individuals that
Figure 2. Specific antibodies to PvAMA-1 are directly correlated with antibody responses to Domain II. The correlation of PvAMA-1
reactivity index and Domain II reactivity index for (A) IgG1 and (B) IgG3 among 214 patients with Plasmodium vivax malaria was determined by
Spearman rank correlation.
doi:10.1371/journal.pone.0021289.g002
Figure 3. Schematic diagram of the structure of PvAMA-1, and the prediction scores for linear B cell epitopes and intrinsically
unstructured/disordered regions (IURs). The region corresponding to the residues 290–307 of Pv-AMA-1 was selected for the synthesis of a
soluble peptide based on the best prediction scores determined for both features. Each green bar represents a predicted B cell epitope, and each red
bar represents a predicted unordered region. The prediction scores represents the average of scores for all amino acids within the region with
prediction values above the cut-offs chosen for significance. The bar color intensities are proportional to the prediction scores found.
doi:10.1371/journal.pone.0021289.g003
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No association between IgG levels against the synthetic peptide
and exposure (determined by number of malaria episodes) was
detected (Figure 5).
In order to determine the immunodominance of the synthetic
peptide SASDQPTQYEEEMTDYQK within PvAMA-1 and DII
antibody responses, an ELISA depletion assay was performed. In
this assay, the IgG reactivity against PvAMA-1 and DII after
depletion of peptide-specific antibodies was reduced by 18% and
33% (P=0.0001 for both), respectively (Figure 6).
Discussion
During the last decades, the development of subunit malaria
vaccine candidates has been thoroughly pursued [46]. Although
malaria vaccine development has been hastened by description of
numerous candidates, no vaccine yet has provided a strong and
lasting immune response [47]. Nonetheless, significant progress has
been achieved as several malarial vaccines are currently undergoing
pre-clinical and clinical trials [11,46,48]. Although more than 70 P.
falciparum vaccine candidates are currently under development and
23 of theses are undergoing clinical testing, only a few P. vivax
vaccine formulations are being assessed in pre-clinical studies, and
sofar, only two candidates (the CSP andthePvs25)havebeen tested
in Phase 1 clinical trials (reviewed in [49]). One of the most
promising components for a malaria blood-stage vaccine is the
apical membrane antigen 1 (AMA-1) due to the efficacy observed
after a blood-stage challenge in animal models [11]. The
observation of a protective outcome demonstrated that vaccination
of mice and monkeys with native [50] or recombinant AMA-1
[10,51] conferred protection from parasite challenge and induced
antibodies that inhibit parasite growth in vitro [17,40,52]. These data
havesparked interesttowardthefurtherclinicaltestinginhumans;a
few reports on Phase Ia trials in malaria-naı ¨ve subjects are already
available for P. falciparum AMA-1 [53,54,55], and the results from
ongoing and planned studies are expected in the near future for
vivax malaria [17]. Although the success of this vaccine will be
determined in field trials under natural conditions of parasite
exposure, the continuous improvement of malaria vaccine design is
still required. For instance, thus far, no recombinant malarial
protein-in-adjuvant formulations have proved sufficiently effica-
cious to encourage further testing [56,57]. Moreover, the
production of high-quality and correctly folded Plasmodium recom-
binant proteins is difficult [58].
In the present study, our focus has been to characterize
naturally antigenic B-cell determinants of the AMA-1 vaccine
antigen in order to select future potential malarial subunit vaccines
using bioinformatics tools and synthetic peptide technology. We
initially confirmed that serum from naturally infected individuals
used for further characterization of B cell epitopes was highly
reactive to recombinant AMA-1 of P. vivax, where more than 60%
of specific IgG recognition was detected among individuals with
patent vivax malaria. In fact, immunoepidemiological studies have
shown that specific antibody responses to AMA-1 are highly
prevalent in individuals naturally exposed to malaria, even with
varying levels of parasite exposure [14,16,39]. However, it is
important to mention that due to the considerable sequence
homology of AMA-1 among Plasmodium species [59], cross-reactive
responses are expected to occur because P. falciparum is responsible
for 16.3% of the registered malaria cases in Brazil [60]. We also
demonstrated a similar proportion of IgG response between AMA-
1 and domain II (DII) during natural infection, which corroborates
a previous report showing that DII is a particularly antigenic and
immunogenic region within AMA-1 [37]. Furthermore, the
analysis of IgG subclasses indicated a predominant IgG1 and
IgG3 antibody production against both AMA-1 and domain II. Of
note, IgG1 and IgG3 antibodies have been implicated in antibody-
mediated protective immunity against malaria [61]. Although the
pattern of IgG subclasses against the recombinant AMA-1 has
been clearly characterized in natural infection [14,17], we are the
first to demonstrate the prevalence of IgG isotypes specific to
domain II in patent infected individuals. It is noteworthy that
equivalent IgG subclass recognition between DII and the full
AMA-1 ectodomain was also observed during natural infection.
Interestingly, our analysis demonstrated that IgG and IgG
subclasses elicited against AMA-1 are significantly associated with
antibody production against DII.
The current understanding of AMA-1 immunity suggests that the
direct action of antibodies is the primary protective mechanism
[17]. Selection of parasitic epitopes that elicit protective antibodies
after immunization would render a strategic approach in the design
of effective vaccines. The recent availability of genomic [62,63],
proteomic [64] and transcriptomic [64,65] data sets for Plasmodium
species and the development of algorithms for B cell epitope
prediction [41,66] have facilitated the identification of promising
vaccine antigens [67] and immunodominant regions within selected
candidates. In the current study, we analyzed the primary sequence
of PvAMA-1 for possible B cell linear epitopes co-occurring with
intrinsically unstructured/disordered regions (IURs). Determinants
containing both B cell linear epitopes and IURs are more likely to
represent a real antigenic/immunogenic region within a protein.
Indeed, the co-occurrence of IURs and linear epitopes increase the
odds that the epitope is present in regions with no secondary
structure (extended regions) that, therefore, are more likely to be
exposed on the surface of the protein [68]. Our results showed that
the prediction of B cell epitopes have identified antigenic regions
distributed all over the three distinct domains of PvAMA-1, which
might represent promising polypeptidic vaccine candidates. Con-
sidering the high degree of amino acid sequence conservation in the
Figure 4. Levels of IgG against the synthetic peptide
SASDQPTQYEEEMTDYQK. Serum samples were selected from
naturally P. vivax-infected individuals who presented previous reactivity
to PvAMA-1 ectodomain only, PvAMA-1 Domain II (DII) only or to both
antigens. Antibody responses are expressed as the reactivity index
detected by enzyme-linked immunosorbent assay. The horizontal
dotted line shows the threshold of positivity at a reactivity index of 1.
Percentage values represent the overall frequency of positive respond-
ers for each group.
doi:10.1371/journal.pone.0021289.g004
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the strong association between AMA-1 and domain II antibody
responses, and the epitope with highest prediction scores for both
analyzed features was found in domain II, we have selected the
peptide SASDQPTQYEEEMTDYQK for further chemical syn-
thesis and immunological testing. Moreover, the analysis of this
specific immunodominant region did not present homology to any
genome sequence of mice and humans (data not shown),
strengthening the rationale for its possible future use in pre-clinical
and clinical trials.
Analysis of antigenicity of the selected peptide using serum from
naturally P. vivax-infected individuals who were previously reactive
to PvAMA-1 only, DII only or to both recombinant proteins
demonstrated that the SASDQPTQYEEEMTDYQK peptide was
recognized by all serum samples that also specifically recognized
domain II. Moreover, serum from infected individuals with no
reactivity to domain II presented a considerable positivity (58.3%)
against the synthetic peptide, suggesting that during natural
infection, there is specific antibody production against this
antigenic epitope, which is probably not detectable when serum
is assayed only against DII. Interestingly, although the number of
malaria episodes has been associated with the frequency of
antibody responses to PvAMA-1 in naturally infected individuals
[39], our results did not show a clear association between IgG
Figure 5. IgG antibody recognition of synthetic peptide in naturally P. vivax-infected individuals with known reactivity to PvAMA-1
ectodomain only, PvAMA-1 Domain II (DII) only or to both antigens. The age (years) and number of malaria episodes are indicated for each
individual. Different levels of IgG antibody production (reactivity index) are represented with different shading patterns.
doi:10.1371/journal.pone.0021289.g005
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exposure to malaria. Finally, the results from the antibody
depletion assay indicated that specific antibodies to the synthetic
peptide would account for up to 18% and 33% of PvAMA-1 and
domain II antibody responses, respectively. Overall, these results
suggest that this AMA-1 linear epitope is highly antigenic during
natural human infections, and it is an important antigenic region
of the domain II of PvAMA-1. Although antibodies are widely
agreed to play a role in protection against blood-stage malaria
[56], the real contribution of the antibody response against this
AMA-1 polypeptide remains to be addressed. Of note, a previous
study establishing the epitope recognition by the invasion-
inhibitory monoclonal antibody 4G2 specific for P. falciparum
AMA-1 has demonstrated the importance not only of conforma-
tional epitopes but also of a singular disordered region with no
electron density between residues 348 and 389 (equivalent to
residues 293 to 334 in PvAMA-1) during parasite invasion [69].
In summary, in the current study, we have identified a highly
antigenic B cell epitope within the PvAMA-1 vaccine candidate
and its serological reactivity during natural infection. Selection of
particular antigenic and immunogenic epitopes within the AMA-1
antigen would represent an interesting perspective to overcome the
hurdles observed in vaccine development, mainly the production
of high-quality and correctly folded proteins expressed heterolo-
gously, as a smaller antigenic polypeptide can facilitate large-scale
production and generation of a chimeric peptide containing
multiple relevant epitopes of malarial antigens. Pre-clinical studies
are currently underway to determine whether the immunization
with this peptide would elicit strong and lasting immunogenicity in
mice as already demonstrated for the recombinant domain II [70].
Supporting Information
Figure S1 MALDI-TOF-TOF analysis of the synthetic
peptide SASDQPTQYEEEMTDYQK.
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